A bridge round is short-term financing - typically a convertible note or SAFE - that extends runway to the next priced round or a defined milestone. Bridges are often structured as convertible notes or SAFEs from existing investors. They work best when there is a near-term, credible milestone, such as an FDA decision or trial readout. Repeated bridges without progress can signal trouble and make later fundraising harder.

Why it matters

Bridges are common in MedTech to span trial enrollment delays or FDA review timelines. 'Bridge to nowhere' is the cautionary phrase: bridges without a clear next milestone often become recapitalizations.

Common pitfalls

•Confusing a bridge round with a long-term financing solution can lead to inadequate planning for future funding needs and potential disruptions to regulatory timelines.
•Failing to clearly define the milestones a bridge round is intended to achieve can result in a "bridge to nowhere," jeopardizing the ability to fund essential regulatory activities.
•Inadequate due diligence regarding the terms and conditions of a bridge round could introduce financial constraints that impact investment in critical quality, regulatory, or cybersecurity infrastructure.
•Underestimating the time and resources required to achieve the milestones funded by a bridge round can lead to subsequent financial crises, potentially affecting product development and regulatory approval processes.
•Poor management of bridge round funds might result in insufficient capital for essential compliance activities, such as clinical data collection or post-market surveillance.

Sources

SVB: bridge financing · SVB
PitchBook - MedTech Coverage · PitchBook
NVCA Model Documents · NVCA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.